nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A Novel PRKAR1A::MET Fusion Dramatic Response to Crizotinib in a Patient with Unresectable Lung Cancer
|
Yang, Yang |
|
|
24 |
1 |
p. e50-e54 |
artikel |
2 |
Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era
|
Gonugunta, Amrit S. |
|
|
24 |
1 |
p. 11-17 |
artikel |
3 |
Clinical Outcomes and Prognosis of Patients With Interstitial Lung Disease Undergoing Lung Cancer Surgery: A Propensity Score Matching Study
|
Ki, Min Seo |
|
|
24 |
1 |
p. e27-e38 |
artikel |
4 |
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial
|
Li, Anna |
|
|
24 |
1 |
p. 82-88 |
artikel |
5 |
Editorial Board
|
|
|
|
24 |
1 |
p. A1 |
artikel |
6 |
Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy
|
Fu, Jing |
|
|
24 |
1 |
p. 29-39 |
artikel |
7 |
Increased Utilization of Stereotactic Body Radiotherapy is Associated with Decreased Disparities and Improved Survival for Early-Stage NSCLC
|
Ganesh, Ashwin |
|
|
24 |
1 |
p. 60-71 |
artikel |
8 |
Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study
|
Mordant MD, PhD, Pierre |
|
|
24 |
1 |
p. 1-10 |
artikel |
9 |
Outcomes Following SBRT vs. IMRT and 3DCRT for Older Patients with Stage IIA Node-Negative Non-Small Cell Lung Cancer > 5 cm
|
Tran, Jessica H. |
|
|
24 |
1 |
p. e9-e18 |
artikel |
10 |
Pathological Stage N1 Limited-Stage Small-Cell Lung Cancer Patients Can Benefit From Surgical Resection
|
Yu, Lian |
|
|
24 |
1 |
p. e1-e8 |
artikel |
11 |
Real-world ALK Testing Trends in Patients With Advanced Non–Small-Cell Lung Cancer in the United States
|
Lin, Huamao M. |
|
|
24 |
1 |
p. e39-e49 |
artikel |
12 |
Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer
|
Schmid, Sabine |
|
|
24 |
1 |
p. 40-50 |
artikel |
13 |
Regression of Malignant Pleural Mesothelioma in Absence of Chemotherapy or Surgery: A Case Series
|
Nief, Corrine A. |
|
|
24 |
1 |
p. 76-81 |
artikel |
14 |
Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers
|
Spitaleri, G. |
|
|
24 |
1 |
p. e19-e26 |
artikel |
15 |
Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report
|
Gazeu, Alexia |
|
|
24 |
1 |
p. 72-75 |
artikel |
16 |
Table of Contents
|
|
|
|
24 |
1 |
p. A2-A4 |
artikel |
17 |
The comparison of Lobe-Specific or Systematic Mediastinal Lymph Node Dissection for Early-Stage Lung Adenocarcinoma With Consolidation Tumor Ratio Over 0.5
|
Sui, Qihai |
|
|
24 |
1 |
p. 51-59 |
artikel |
18 |
The Value of Radiotherapy in Patients With Resectable Stage IIIA Non–Small-Cell Lung Cancer in the Era of Individualized Treatment: A Population-Based Analysis
|
Liu, Bohao |
|
|
24 |
1 |
p. 18-28 |
artikel |